Swiss National Bank Acquires 2,000 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Swiss National Bank grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 0.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 321,600 shares of the biopharmaceutical company's stock after buying an additional 2,000 shares during the period. Swiss National Bank owned 0.29% of Regeneron Pharmaceuticals worth $338,079,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. International Assets Investment Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company's stock valued at $926,078,000 after purchasing an additional 879,916 shares in the last quarter. Capital International Investors boosted its position in Regeneron Pharmaceuticals by 7.3% during the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company's stock valued at $3,011,640,000 after acquiring an additional 213,038 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Regeneron Pharmaceuticals by 25.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company's stock worth $868,757,000 after acquiring an additional 184,561 shares during the period. Swedbank AB bought a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $129,257,000. Finally, Epoch Investment Partners Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at approximately $99,667,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

REGN has been the topic of several recent research reports. Piper Sandler reduced their price target on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an "overweight" rating on the stock in a research note on Friday, November 1st. JPMorgan Chase & Co. reduced their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating on the stock in a research report on Thursday, October 24th. Barclays lowered their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating for the company in a research report on Friday, November 1st. Evercore ISI cut their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating on the stock in a report on Thursday, October 24th. Finally, Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a report on Friday. They set an "outperform" rating and a $1,150.00 target price for the company. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $1,099.55.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded down $25.70 on Friday, reaching $756.81. The stock had a trading volume of 1,374,549 shares, compared to its average volume of 850,545. The stock has a market cap of $83.17 billion, a P/E ratio of 18.73, a price-to-earnings-growth ratio of 2.86 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a 1 year low of $753.69 and a 1 year high of $1,211.20. The company has a 50 day simple moving average of $985.21 and a 200 day simple moving average of $1,034.89.

Insiders Place Their Bets

In related news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.48% of the company's stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.